Cerenia Maropitant for Dogs and Cats

Of course. Let's break down maropitant. It's one of the most impactful drugs in small animal practice, but understanding its nuances is key to using it effectively and safely.

Maropitant (Cerenia®)

Mechanism of Action:
Maropitant is a potent and selective neurokinin-1 (NK-1) receptor antagonist. Its efficacy comes from blocking the binding of Substance P, the primary ligand for NK-1 receptors. This action is critical because NK-1 receptors are located in key areas controlling emesis:
* Centrally: In the chemoreceptor trigger zone (CTZ) and the emetic center of the brainstem.
* Peripherally: On vagal afferent nerve terminals in the gastrointestinal tract.

By blocking Substance P in both locations, maropitant inhibits a final common pathway for virtually all emetic stimuli (e.g., visceral, chemoreceptor, vestibular), making it a uniquely broad-spectrum antiemetic.

Canine Dosing & Indications:

* Acute Vomiting:
* Injectable (SQ/IV): 1.0 mg/kg q24h. The FDA label is for up to 5 consecutive days.
* Oral: 2.0 mg/kg PO q24h. The FDA label is for up to 14 consecutive days.
* Rationale: The oral dose is higher to account for incomplete bioavailability (~24-37%).

* Motion Sickness Prevention:
* Oral: 8.0 mg/kg PO q24h. Administer at least 2 hours prior to travel with a small meal to minimize pre-dose vomiting.
* Rationale: Higher CNS concentrations are required to effectively block the overwhelming vestibular input to the emetic center during motion. This dose is significantly higher than the antiemetic dose and should not be used for general vomiting.

* Visceral Pain (Off-Label Adjunct):
* Dose: 1.0 mg/kg IV or SQ q24h.
* Rationale: Substance P is also a key neurotransmitter in visceral pain pathways (e.g., pancreatitis, ovariohysterectomy, enterotomy). By blocking NK-1 receptors, maropitant can provide a degree of visceral analgesia and has a documented MAC-sparing effect for inhalant anesthetics. It is an adjunct, not a primary analgesic.

Feline Use (Off-Label):

* Dosing: The dose is extrapolated from canine studies and clinical use: 1.0 mg/kg SQ/IV q24h. The oral dose is typically 2.0 mg/kg PO q24h, though data is more limited.
* Injection Site Reactions: The stinging associated with SQ injection is a significant clinical issue. This is due to the formulation's acidic pH (~4.0), which is necessary to keep maropitant in solution.
* Mitigation: Refrigerating the vial prior to injection can reduce the sensation. Diluting 1:1 with sterile saline or LRS immediately before administration is a common off-label technique to buffer the pH, but be aware this is not supported by the manufacturer and could theoretically affect stability.

Key Pharmacokinetic Considerations:

* Metabolism: Primarily hepatic, via CYP2D15 and CYP3A12.
* Minimum Age: The label recommends against use in dogs <8 weeks for vomiting and <16 weeks for motion sickness. This is due to immature hepatic enzyme systems in neonates, which can lead to impaired drug clearance, accumulation, and potential toxicity (e.g., bone marrow hypoplasia noted in one study of very young puppies at high doses).

Drug Interactions:

Maropitant is >99% protein-bound. Its primary clinically relevant interaction is competition for plasma protein binding sites.
* Use with caution alongside other highly protein-bound drugs (e.g., NSAIDs, phenobarbital, furosemide). In a healthy patient, this is rarely an issue. However, in a critically ill, hypoalbuminemic patient, displacement could increase the free, active fraction of either drug, potentially increasing the risk of adverse effects.

Contraindications & When NOT to Use:

GI Obstruction or Toxin Ingestion: This is the most critical contraindication. Maropitant is so effective it can mask the clinical sign of vomiting, potentially delaying diagnosis and surgical intervention for a foreign body obstruction until the patient is critically ill. Always rule out obstruction before using maropitant as a sole therapy for protracted vomiting.

Hepatic Dysfunction: As the drug is hepatically metabolized, a dose reduction (e.g., 25-50%) and careful monitoring are warranted in patients with significant liver disease.

Cardiac Disease: Maropitant has weak calcium channel blocking activity at doses higher than recommended. While generally safe, use with caution in patients with pre-existing cardiac disease or those receiving calcium channel blockers (e.g., amlodipine, diltiazem).

In summary, maropitant is a first-line, highly effective antiemetic. Your primary responsibility is to ensure its use is coupled with a diagnostic plan and not used to mask a condition, like an obstruction, that requires definitive treatment.